Loading...

Bronchiectasis Awareness And Home Care Will Drive Lasting Success

Published
21 Feb 25
Updated
16 Nov 25
n/a
n/a
AnalystConsensusTarget's Fair Value
n/a
Loading
1Y
-13.0%
7D
2.5%

Author's Valuation

US$35.2526.5% undervalued intrinsic discount

AnalystConsensusTarget Fair Value

Shared on 16 Nov 25

Fair value Increased 0.71%

ELMD: Double-Digit Revenue Gains And Buybacks Will Drive Shares Higher

Electromed's analyst fair value target increased slightly from $35.00 to $35.25, as analysts cite consistent double-digit revenue growth forecasts and improving operational efficiency in recent reports. Analyst Commentary Bullish Takeaways Bullish analysts highlight Electromed's consistent double-digit revenue growth forecasts and note that ongoing top-line expansion is expected in the coming years.

Shared on 01 May 25

Fair value Decreased 7.04%

Shared on 23 Apr 25

AnalystConsensusTarget made no meaningful changes to valuation assumptions.

Shared on 17 Apr 25

AnalystConsensusTarget made no meaningful changes to valuation assumptions.

Shared on 09 Apr 25

AnalystConsensusTarget made no meaningful changes to valuation assumptions.

Shared on 02 Apr 25

Fair value Increased 5.14%

AnalystConsensusTarget made no meaningful changes to valuation assumptions.

Shared on 26 Mar 25

AnalystConsensusTarget made no meaningful changes to valuation assumptions.

Shared on 19 Mar 25

AnalystConsensusTarget made no meaningful changes to valuation assumptions.

Shared on 13 Mar 25

Fair value Increased 6.90%

AnalystConsensusTarget made no meaningful changes to valuation assumptions.